Form 4: DarioHealth Corp. Executive Granted Stock Options

Steven Charles Nelson, Chief Commercial Officer of DarioHealth Corp., received stock options to purchase shares of common stock, according to a recent SEC filing.

Summary

• Steven Charles Nelson, the Chief Commercial Officer of DarioHealth Corp., was granted stock options on June 5, 2024.
• The options are for the purchase of common stock.
• Nelson received options for 500,000 shares, 400,000 shares, and 1,350,000 shares.
• The exercise price for all options is $1.35.
• The options expire on June 5, 2034.
• Vesting schedules vary, with some options vesting over three years, some immediately upon achieving revenue milestones for 2024, and others vesting quarterly upon achieving revenue milestones for 2025, 2026, and 2027.

Sentiment

Score: 7

Explanation: The document indicates a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management with shareholder interests. The vesting conditions tied to revenue targets are a positive sign.

Positives

• The granting of stock options to the Chief Commercial Officer aligns his interests with those of the shareholders.
• The vesting schedules tied to revenue milestones incentivize the executive to drive company growth.
• The long-term expiration date of the options (June 5, 2034) encourages a long-term focus.

Risks

• The achievement of revenue milestones required for vesting is not guaranteed.
• The value of the stock options is dependent on the future performance of DarioHealth Corp.'s stock price.

Future Outlook

The vesting of the options is contingent upon the achievement of certain revenue milestones in future years, indicating a focus on growth.

Industry Context

Stock options are a common form of executive compensation in the healthcare technology industry, used to incentivize performance and align management interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in growth-oriented sectors like healthcare technology.
• Companies like Teladoc Health and Livongo (prior to its acquisition by Teladoc) have used similar stock option plans to incentivize their leadership teams.
• The vesting schedules tied to revenue milestones are also common, aligning executive compensation with company performance, similar to practices seen at companies like Cerner and Epic Systems.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Chief Commercial Officer to drive revenue growth.
• Employees may be motivated by the company's focus on achieving revenue milestones.
• The granting of stock options has no immediate impact on customers, suppliers, or creditors.

Key Dates